• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Riverain’s Chest X-Ray Comparison Tool Gets FDA Nod

Article

Temporal Comparison software compares current and prior chest X-rays to help identify nodules that may be early-stage lung cancer.

Riverain Technologies, a Dayton, Ohio-based medical technology company, has received FDA 510(k) clearance for its Temporal Comparison software, which compares current and prior chest X-rays and can help identify nodules that may be early-stage lung cancer, the company announced.

The technology targets differences between the X-rays, drawing attention to what could be an emerging or enlarging tumor. The software aligns the two images to produce a difference image, which the company said allows radiologists to identify subtle changes more clearly.

In a study of 422 pairs of chest X-rays, 15 radiologists demonstrated an average of 12.4 percent improvement in sensitivity for actionable solitary pulmonary nodules using the software, compared to results viewing the X-rays side by side, the company said.

The software can be used with Riverain’s Bone Suppression software, which removes the bones from the image to make differences more conspicuous.
 

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.